

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-7 (Canceled).

8. (Currently Amended) A percutaneous absorption preparation which comprises a skin contacting base containing a compound having angiotensin II antagonistic activity and a skin permeability regulator, and a support, wherein the skin permeability regulator comprises a fatty acid ester, a polyol and a nonionic surfactant and wherein the compound having angiotensin II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate ~~or a salt thereof~~.

9-10. (Canceled).

11. (Previously Presented) The preparation according to claim 8, wherein the fatty acid ester is an ester of C₁₀₋₂₂ carbonic acid and C₁₋₁₂ alkylalcohol.

12. (Previously Presented) The preparation according to claim 8, wherein the fatty acid ester is isopropyl myristate, isopropyl palmitate, butyl myristate or diethyl sebacate.

13. (Previously Presented) The preparation according to claim 8, wherein the fatty acid ester is isopropyl myristate.

14. (Canceled).

15. (Previously Presented) The preparation according to claim 8, wherein the polyol is ethylene glycol, propylene glycol, 1,3-butylene glycol, polyethylene glycol or glycerin.

16. (Previously Presented) The preparation according to claim 8, wherein the polyol is propylene glycol.

17. (Canceled).